IXICO PLC (LSE:IXI, OTC:PHYOF) CEO Bram Goorden talked with Proactive's Stephen Gunnion about the company’s strong first-half performance, marked by a 26% increase in revenue year-on-year. Goorden outlined the company’s diversification strategy, which has included moving beyond rare neurodegenerative diseases into broader areas such as Alzheimer’s and Parkinson’s, supported by novel imaging algorithms.
The CEO highlighted that IXICO also extended projects with existing clients due to its leadership in biomarker science. “We were able to expand some of the work that we're doing with existing clients,” he said, citing the company's positioning as a partner in biomarker development.
Goorden detailed IXICO’s “Innovate, Lead, Scale” strategy, explaining the focus on platform innovation, increased market presence, and investment in operational scale, particularly in the United States. “We’ve started to deliver on platform,” he noted, adding that the innovations were already fueling commercial deals.
The interview also covered new verticals, notably IXICO’s collaborations with diagnostics companies working on blood-based biomarkers. These ventures are complementary to the company’s neuroimaging expertise and represent a new revenue stream with future integration potential.
Looking ahead, Goorden said IXICO enters the second half of the year with £5 million in cash and a £13.1 million order book. The company expects more deals in the diversified disease space and further innovation milestones.
Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content.
#IXICO #AlzheimersResearch #ParkinsonsDisease #Neuroimaging #Biomarkers #Diagnostics #HealthcareInnovation #ClinicalResearch #BiotechNews #InvestingInHealthcare #ProactiveInvestors
